Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - teriparatide, quantity: 250 microgram - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate; hydrochloric acid; mannitol; sodium hydroxide; water for injections; metacresol - forteo is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. forteo is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - teriparatide 250 µg/ml (rhpth(1-34));   - solution for injection - 250 mcg/ml - active: teriparatide 250 µg/ml (rhpth(1-34))   excipient: glacial acetic acid hydrochloric acid mannitol metacresol sodium acetate sodium hydroxide water for injection - forteo, in combination with calcium and vitamin d, is indicated for the treatment of osteoporosis in postmenopausal women and in men at high risk of fracture.

European Union - English - EMA (European Medicines Agency)

forte healthcare limited - fluoxetine - psychoanaleptics - dogs - as an aid in the treatment of separation-related disorders in dogs manifested by destruction and inappropriate behaviours (vocalisation and inappropriate defecation and / or urination) and only in combination with behavioural-modification techniques.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - calcium; cholecalciferol - chewable tablet - 500 mg/800 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - calcium; cholecalciferol - film-coated tablet - 500 mg/800 international unit(s) - calcium, combinations with vitamin d and/or other drugs

Malta - English - Medicines Authority

viatris healthcare limited damastown industrial park, mulhuddart, dublin 15, dublin , ireland - hard capsule - acemetacin 60 mg - antiinflammatory and antirheumatic products

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - calcium; cholecalciferol - chewable tablet - calcium, combinations with vitamin d and/or other drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

viatris healthcare limited - calcium; cholecalciferol - film-coated tablet - calcium, combinations with vitamin d and/or other drugs

Ireland - English - HPRA (Health Products Regulatory Authority)

forte healthcare ltd - bovine coronavirus strain c-197 (inactivated); bovine rotavirus strain tm-91, serotype g6p1 (inactivated). ; escherichia coli strain ec/17, (inactivated) expressing f5(k99) adhesin - emulsion for injection - . - bovine rotavirus + bovine coronavirus + escherichia - cattle - immunological - inactivated vaccine

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - furosemide 500mg;   - tablet - 500 mg - active: furosemide 500mg   excipient: colloidal silicon dioxide lactose magnesium stearate maize starch maltodextrin - frusemide in a high-dosage formulation such as urex forte (500 mg tablets) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting. high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l/day dialysis has to be used.